Stéphane Bancel, Moderna CEO (Markus Schreiber/AP Images)
March 27, 2024 04:04 PM EDT
R&D

Here's how Mod­er­na is think­ing about the fu­ture of its vac­cines

Max Gelman

Senior Editor

Mod­er­na laid out its ex­pec­ta­tions for sev­er­al vac­cine mar­kets Wednes­day morn­ing at an in­vestor event as it con­tin­ues mov­ing through its year …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

No­vo de­clares Phase 3 car­diac out­comes tri­al win for oral GLP-1

Star­board takes ac­tivist stake in J&J con­sumer spin­out Ken­vue

For­mer Karuna crew quick­ly as­sem­bles $225M for next neu­ro bet at Sea­port

Q3 biotech roundup: The 2024 turn­around sput­ters in­to a crit­i­cal Q4 fi­nale

As­traZeneca-backed CD­MO Nu­cle­us Ra­dio­Phar­ma to boost com­mer­cial ca­pac­i­ty

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times